OncoMatch

OncoMatch/Clinical Trials/NCT06104553

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

Is NCT06104553 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including SHR-A1912; R-Chemo and SHR-A1912; R-Chemo for b-cell non-hodgkin's lymphoma.

Phase 1/2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.NCT06104553Data as of Jun 2026Location: China

Treatment: SHR-A1912; R-Chemo · SHR-A1912; R-ChemoThis study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

SHR-A1912; R-ChemoSHR-A1912; R-Chemo

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 0 prior lines

Must have received: systemic anti-tumor therapy — relapsed/refractory cohort: at least one (≥ 1) line of prior systemic therapy

Relapsed and/or refractory disease after at least one (≥ 1) line of prior systemic therapy (relapsed/refractory cohort)

Cannot have received: autologous stem cell transplant

Exception: allowed if >12 weeks before first study treatment

Received autologous stem cell transplantation within 12 weeks before the first study treatment

Cannot have received: allogeneic stem cell transplant

previously received allogeneic stem cell transplantation

Cannot have received: CAR-T cell therapy

Exception: allowed if >12 weeks before first study treatment

received Car-T cell therapy within 12 weeks before the first study treatment

Cannot have received: anti-tumour treatment

Exception: allowed if >2 weeks before first study treatment

Received anti-tumour treatment within 2 weeks before the first study treatment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06104553 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant, CAR-T cell therapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify